Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
The latest announcement is out from Ovid Therapeutics (OVID).
Ovid Therapeutics Inc. has announced that Thomas Perone, previously serving as General Counsel, Chief Compliance Officer and Corporate Secretary, will be departing the company due to workforce reduction but will remain as a consultant until January 2025. Under the new Consulting Agreement, Perone will be paid up to $55,000 and his equity awards will continue to vest through the consulting term, alongside agreeing to certain post-termination restrictions including non-solicitation.
Find detailed analytics on OVID stock on TipRanks’ Stock Analysis page.
